Citation

Can AT, Mitchell JS, Dutton M, Bennett M, Hermens DF, Lagopoulos J. Psychiatry Clin. Neurosci. 2023; ePub(ePub): ePub.

Copyright

(Copyright © 2023, John Wiley and Sons)

DOI

10.1111/pcn.13572

PMID

37329495

Abstract

Suicidality is a prevalent mental health condition, and managing suicidal patients is one of the most challenging tasks for healthcare professionals due to the lack of rapid-acting, effective psychopharmacological treatment options. According to the literature, suicide has neurobiological underpinnings that are not fully understood, and current treatments for suicidal tendencies have considerable limitations. To treat suicidality and prevent suicide, new treatments are required; to achieve this, the neurobiological processes underlying suicidal behaviour must be thoroughly investigated. Although multiple neurotransmitter systems, particularly serotonergic systems, have been studied in the past, less has been reported in relation to disruptions in glutamatergic neurotransmission, neuronal plasticity and neurogenesis that result from stress-related abnormalities of the hypothalamic-pituitary-adrenal (HPA) system. Informed by the literature which reports robust anti-suicidal and anti-depressive properties of subanaesthetic doses of ketamine, this review aims to provide an examination of the neurobiology of suicidality (and relevant mood disorders) with implications of pertinent animal, clinical and post-mortem studies. We discuss dysfunctions in the glutamatergic system, which may play a role in the neuropathology of suicidality and the role of ketamine in restoring synaptic connectivity at the molecular levels. This article is protected by copyright. All rights reserved.

Language: en

Keywords

depression; suicidality; glutamate; ketamine; glutamatergic system